A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.


Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter

Federal Circuit Cour

By Seán Finan – Edited by Grace Truong McRO, Inc. v. ...


Flash Digest: News i

By Alex Noonan – Edited by Filippo Raso California Supreme Court ...


Second Circuit Holds

June Nam - Edited by Ding Ding TCA Television Corp. v. ...

Fed. Cir. Flash Digest

Flash Digest: News i

By Wendy Chu - Edited by Kayla Haran Delaware Supreme Court ...


Federal Circuit Flas

By Haydn Forrest - Edited by Henry Thomas Affinity Labs of ...